Mesenchymal Stromal Cells Derived from Canine Adipose Tissue: Evaluation of the Effect of Different Shipping Vehicles Used for Clinical Administration

Int J Mol Sci. 2024 Mar 18;25(6):3426. doi: 10.3390/ijms25063426.

Abstract

Mesenchymal Stromal Cells (MSCs)-based therapies are rapidly gaining interest in veterinary medicine. Cellular therapy represents a new challenge for practitioners and requires precise coordination between the cell processing laboratory and the veterinary clinic. Cryopreservation is the best method to provide fast, in-time, and long-distance delivery of cells for therapeutic applications. However, potentially toxic cryoprotectants and xenobiotic products make the direct administration of cells impracticable for patients. Alternatively, the cells may be resuspended in a ready-to-use vehicle and shipped to the veterinary clinic. In this study, two nutrient-poor vehicles (physiologic saline and ringer lactate solutions) and two nutrient-rich vehicles (the releasate derived from autologous Platelet Poor Plasma and Platelet Rich Plasma) were tested on adipose tissue-derived canine MSCs (AD-MSCs). AD-MSCs stored for 2, 4, or 24 h in the different media were compared regarding mortality, metabolic activity, and replicative capacity. Furthermore, antioxidant activity and the pattern of expression of genes related to AD-MSCs function were performed following 24 h of storage. The results showed that all the different vehicles preserve cell vitality and replication following short-term storage. In long-term storage, the vehicle and cell density affect cell vitality, proliferation, and gene expression (CCL-2, CXCR-4, and TSG-6). Nutrient-rich vehicles seem better suited to preserve cell functionalities in this contest.

Keywords: cell shipment; clinical administration; dog; mesenchymal stromal cells; storage vehicle; veterinary regenerative medicine.

MeSH terms

  • Adipose Tissue*
  • Animals
  • Cell Differentiation
  • Cell Proliferation
  • Cell- and Tissue-Based Therapy
  • Cells, Cultured
  • Cryoprotective Agents / pharmacology
  • Dogs
  • Humans
  • Mesenchymal Stem Cells* / metabolism

Substances

  • Cryoprotective Agents

Grants and funding

This research received no external funding.